NCI-designated Consortium Cancer Center
|
|
|
|
|
Karen Knudsen, MBA, Ph.D.
CEO, American Cancer Society, Inc.
Seminar Title: "Working together to improve lives through discovery, advocacy, & patient support: A Focus on Advanced Prostate Cancer"
TODAY - Monday, July 18, 2022
4:00 p.m. - 5:00 p.m.
Location: MCC Goldberg Auditorium (2nd floor Moores Cancer Center)
This is a hybrid seminar, Zoom meeting link below.
UC San Diego COVID protocols will be adhered to, with details to follow.
|
|
|
The Office of the Vice Chancellor for Health Sciences is delighted to host a series of guest lectures as part of the Moores Cancer Center Director recruitment effort. Each lecturer will highlight their personal achievements in education, research, and/or clinical care, as well as a brief vision for the Cancer Center.
|
|
|
|
|
Robert Winn, M.D.
Director, Massey Cancer Center
Virginia Commonwealth University
Tuesday, July 19, 2022
9:00 a.m. - 10:00 a.m. (UPDATED TIME)
Goldberg Auditorium
(in-person capacity limited to 60)
ZOOM MEETING LINK
|
|
|
COE Pilot Project Webinar for MCC Researchers
Monday, July 25, 2022
11:00 a.m. - 12:00 p.m.
Speakers:
Elena Martinez, Ph.D.
Corrine McDaniels-Davidson, Ph.D.
|
|
|
Accepting Applications for Associate Director,
Diversity, Equity, and Inclusion
|
|
|
|
|
Moores Cancer Center (MCC) is recruiting an Associate Director of Diversity, Equity, and Inclusion (DEI) to lead DEI initiatives that foster an inclusive and anti-racist environment for all members and employees of the MCC. The position has been established to support the National Cancer Institute’s commitment to ensure that (1) all Americans share equally in the medical advances that result from cancer research and (2) current disparities in the cancer burden are reduced or eliminated. As such, the position will provide strategic leadership, coordination, and implementation of DEI-related programs, initiatives, policies, and evaluative activities to enhance the diversity of MCC staff, faculty, students, and leadership.
For more information on this exciting opportunity, please visit the link below.
DEADLINE: July 31, 2022
MORE INFO
|
|
|
Accepting Applications for Vice Chair, Data and Safety Monitoring Committee (DSMC)
|
|
|
|
|
Compensation
Effort: 5% up to NIH cap
Required Qualifications
Faculty member of UCSD, SDSU, or LJI with experience as a PI of a cancer clinical trial
Moores Cancer Center (MCC) Member
Experience as PI/Site PI of Phase I/II investigator-initiated trials
Preferred Qualifications
An ideal candidate would have experience in both industry sponsored and investigator-initiated cancer therapeutics trials
Detail oriented
Committed to maintaining the integrity of clinical trials at MCC and executing the Data Safety and Monitoring Plan as written in the Cancer Center Support Grant
Time Commitment
2-4 hours per month for Committee meetings plus time to review material prior to meetings; more depending on level of involvement with other projects or potential of ad hoc reviews
Term
Recommended to be 3 years
DEADLINE EXTENDED TO JULY 31, 2022
MORE INFO
|
|
|
Division of Regenerative Medicine Seminar Series
"Identifying Signatures of Neural Stem Cell State”
Monday, July 18, 2022
3:00 p.m. - 4:00 p.m.
Darcie Moore, Ph.D.
Assistant Professor
Department of Neuroscience
University of Wisconsin – Madison
ZOOM MEETING LINK
Hosted by: Rob Signer, Ph.D.
For more information, contact: drmseminarseries@ucsd.edu (858) 822-4258, or mellison@health.ucsd.edu
To encourage open and engaging scientific discussions, please remember all presentations and discussions will be confidential and should not be discussed elsewhere without authorization from the presenters.
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
Wednesday, July 20, 2022
2:00 p.m. - 3:00 p.m.
Virtual Workshop: "Federal Grant Opportunities in Healthcare"
Moores Cancer Center is partnering with the Office of Congressman Scott Peters to present a panel for those in the community who would like to learn more about how to apply to federal grants.
Speakers include Dr. James Murphy and Dr. Elena Martinez, who will be sharing insights and experiences in this process.
ZOOM MEETING LINK
|
|
|
Saturday, July 23, 2022
9:00 a.m. - 10:00 a.m.
"Keeping Kids Healthy: HPV Vaccinations"
Moores Cancer Center is partnering with Assembly Member Dr. Akilah Weber’s office to present HPV vaccination information to the community.
Speakers:
Maya Kumar, M.D., UC San Diego Health
Mike West, J.D., HPV Cancer Survivor and Advocate
Andrew Gonzalez, Champions for Health
|
|
|
August 1–5: California HPV Vaccine Week
Look out for events and information on HPV vaccination learning opportunities! Partner Assemblymember Dr. Akilah Weber is introducing a resolution in the state assembly. Be sure to follow us on Twitter @UCSDCancer_COE for updates. More to come!
MORE INFO
|
|
|
Saturday, August 13, 2022
10:00 a.m. - 1:00 p.m.
"Backpack Giveaway and HPV Vaccination Clinic"
Moores Cancer Center is partnering with Assembly Member Dr. Akilah Weber’s office to make HPV vaccinations available via our community partner Champions for Health. Cancer education also will be provided at the event.
Location: Lemon Grove Recreation Center
REGISTER HERE
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITY
|
|
|
2022 Pediatric Cancer Research – Special Grant Opportunity & Significantly Larger Awards V Scholar or Translational or All-Star
$600,000 - $1,000,00 (depending on mechanism)
PURPOSE OF AWARD: Due to exceptional fundraising levels in 2022, the VFoundation is offering an additional pediatric cancer research grant opportunity. This grant opportunity will be implemented through one of three grant mechanisms: VScholar, Translational, or All-Star grant types.
MCC Limited Submission LOIs must be submitted to Angela Ballantyne, Ph.D. by the internal deadline of Thursday, August 11, 2022, at 5 p.m.
|
|
|
NIH Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations (R24)
Funding Available: $350,000
Funds are to modernize operations of existing research facilities through the purchase and installation of advanced equipment that enable and enhance a broad range of research-supporting activities. Supported equipment must be substantially used in a laboratory research core facility, animal facility, or similar shared-use research space to ensure broad benefits for the institutional research community. Requests must be justified by research-related demands for the modernization of research-supporting functions or for the advancement of facility operations. Equipment must benefit the larger biomedical research enterprise at the applicant institution and represent a technological step forward.
Internal Limited Submission Deadline: Tuesday, August 9, 2022, at 5:00 pm (1 submission per institution)
Funding Organization's Deadline: Monday, November 7, 2022
MORE INFO
|
|
|
HHMI Freeman Hrabowski Scholars Program
Awards will cover full salary, benefits, and a research budget of ~$2M direct /5y
This new program will support outstanding basic researchers, including physician-scientists, who have strong potential to become leaders in their fields and to advance diversity, equity, and inclusion.. Eligible research areas include all basic biomedical science disciplines, as well as plant biology, evolutionary biology, biophysics, chemical biology, biomedical engineering, and computational biology. Applicants must have begun a tenure-track faculty position on or after July 1, 2018, or have accepted an offer for a position that will begin no later than July 1, 2023. Up to 30 awards will be made in 2023; future competitions are anticipated every other year. Watch the recording of an information session.
Applications due: September 28, 2022
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Damon Runyon Cancer Research Foundation Fellowship Award
$60,000 - $66,000 in stipend support for four years plus additional educational or scientific expenses and a child dependent allowance
The Damon Runyon Cancer Research Foundation is a leading nonprofit organization that funds brave and bold young cancer researchers.
Damon Runyon views cancer research very broadly, including the full spectrum of basic questions important to normal human biology and carcinogenesis, as well as development of new platforms and technologies. We encourage all theoretical and experimental research that has the potential to provide insights into cancer and the search for cancer causes, mechanisms, therapies and prevention for all types of cancer.
Application Deadline: August 15, 2022
MORE INFO
|
|
|
Susan G. Komen Career Catalyst Research (CCR) Grants for Early Career Investigators
Funding Level: Up to $450,000 over 3 years ($150,000 per year, combined direct and indirect costs)
Through this grant mechanism, we seek to support those who will emerge as the next generation of key leaders in the quest to end breast cancer.
Research Focus Areas: CCR Grants will support outstanding research focused on two important aspects of precision medicine: the development of next generation-targeted therapies and the development of interventions to eliminate breast cancer health disparities. Proposals that are basic, translational, clinical, or population sciences and meet at least one focus area listed below will be considered.
Beyond PARP inhibitors: Next-generation breast cancer therapies targeting the genome and epigenome
Beyond T-Cells: Next generation breast cancer immunotherapy
Closing the Gap: New, approaches to address multi-level contributors to breast cancer disparities
Letters of Intent Deadline is Extended to August 1, 2022, 1:00 p.m. EST
Full Application Due: October 5, 2022, by 1 p.m., EST
MORE INFO
|
|
|
DOD Breast Cancer Research Program: Transformative Breast Cancer Consortium Award
$25M direct for up to 4 years
The U.S. Department of Defense, Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer.
Pre-Application Deadline: August 8, 2022
MORE INFO
|
NCCN, Pfizer and EMD Serono Quality of Care Initiative to Improve the Treatment of Locally Advanced or Metastatic Bladder Cancer Patients
Intent is to fund individual projects capped at $150,000 (direct
and indirect costs) although smaller, lower-costs projects are
encouraged. Funding greater than $150,000 will be considered for
exceptional proposals with detailed budget justification.
National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Pfizer Global Medical Grants (GMG) and EMD Serono to offer a second grant opportunity to support Quality Improvement projects that will advance the quality of care, including guideline concordant care, and best practices around treatment for patients with Locally Advanced or Metastatic Disease (Stage IV; according to the AJCC TNM staging system) Bladder Cancers.
The intent of the RFP is to encourage NCCN Member Institutions and non-NCCN Member Institutions to submit proposals describing concepts and ideas around how to improve the quality of care, including guideline concordant care, and best practices around treatment for patients with Locally Advanced or Metastatic Disease Bladder Cancers.
Submit Proposal by Thursday, August 18, 2022 by 5:00 pm ET
MORE INFO
|
Administrative Supplements to Support Cancer Disparity Collaborative Research
Award: $150,000 direct for 1 year
The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to (1) promote new cancer disparities research among investigators who do not normally conduct it and (2) encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. Cancer disparities research includes, but is not limited to, basic, translational, behavioral, observational, interventional, environmental, and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden, and/or response to treatment in racial/ethnic minorities and/or underserved populations.
Deadline: September 6, 2022
|
MD22-008 Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
Award: $500K direct/year for up to 5 years
To support research that seeks to (1) understand the underlying mechanisms and (2) test interventions that address and mitigate the impact of health-related misinformation and disinformation on health disparities and the populations that experience health disparities.
Deadline: November 13, 2022
MORE INFO
|
Early-Stage/Advanced/Sustained Development of Informatics Technologies for Cancer Research and Management (R21/U01/U24 Clinical Trial Optional
Award: $275K unlimited direct costs 2-5 years, depending on mechanism
This component of the NCI's Informatics Technology for Cancer Research (ITCR) Program targets the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum.
Deadline: November 17, 2022
|
|
|
Melanoma Research Alliance (MRA) RFP for Team Science Awards focused on patient-centric clinical trials, jointly funded by The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and MRA
$1.5 million
These awards will fund clinical trials with the potential to provide significant impact to melanoma patients. These awards seek to support novel, interventional clinical trials with the goal of making a significant difference to melanoma patients in the short term. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, including planning and dissemination.
Letters of Intent due 11:59 p.m. ET, October 5, 2022
Estimated LOI decisions: November 18, 2022
Invited Full Proposals due 11:59 pm ET, January 18, 2023
|
|
|
Administrative Supplements to Support Cancer Disparity Collaborative Research
Award: $150,000 direct for 1 year
The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to (1) promote new cancer disparities research among investigators who do not normally conduct it and (2) encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. Cancer disparities research includes, but is not limited to, basic, translational, behavioral, observational, interventional, environmental, and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden, and/or response to treatment in racial/ethnic minorities and/or underserved populations.
Deadline: September 6, 2022
|
MD22-008 Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional)
Award: $500K direct/year for up to 5 years
To support research that seeks to (1) understand the underlying mechanisms and (2) test interventions that address and mitigate the impact of health-related misinformation and disinformation on health disparities and the populations that experience health disparities.
Deadline: November 13, 2022
MORE INFO
|
|
|
|
|
Tuesday, October 11, 2022
UC San Diego, Moores Cancer Center
Delivering Discoveries Annual Scientific Retreat
Location: Scripps Seaside Forum
8610 Kennel Way, La Jolla, CA 92037
|
|
|
Thursday to Friday, October 20-21, 2022
Time: TBD
Sanford Stem Cell Annual Symposium co-hosted by Moores Cancer Center, Hematologic Malignancies Program
Location: Sanford Consortium, Duane J. Roth Auditorium
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
- Recent breakthroughs in regenerative medicine
- Stem cell regeneration in several disease areas
- Interactive discussion panels regarding stem cells in space and stem cell clinical trials
Hosted by:
Catriona Jamieson, M.D., Ph.D., Deputy Director of Moores Cancer Center, Director of the Sanford Stem Cell Clinical Center, and Chief of the Division of Regenerative Medicine and Alysson Muotri, Ph.D., Co-Director, Stem Cell Program
Keynote Speakers:
Derrick Rossi, Ph.D., Co-Founder, Moderna; Elizabeth Blackburn, Ph.D., Professor, UC San Francisco; and Thomas C. Sudhof, M.D., Professor, Stanford University
MORE INFO
|
Tuesday to Saturday, November 8-12, 2022
Join Us in Person at SITC 2022
37th Annual Meeting & Pre-Conference Programs
Location: Boston Convention and Exhibition Center, Boston, MA. Virtual participation also available at the same registration rates.
REGISTER TODAY!
|
Saturday, January 28, 2023
Prostate Cancer Patient Summit
More information to come!
|
|
|
Newly opened clinical trials (June, 2022)
|
|
|
- Eschweiler, S., Ramírez-Suástegui, C., Li, Y., King, E., Chudley, L., Thomas, J., Wood, O., von Witzleben, A., Jeffrey, D., McCann, K., Simon, H., Mondal, M., Wang, A., Dicker, M., Lopez-Guadamillas, E., Chou, T. F., Dobbs, N. A., Essame, L., Acton, G., Kelly, F., Halbert, G, Sacco, J. J., Schache, A. G., Shaw, R., McCaul, J. A., Paterson, C., Davies, J. H., Brennan, P. A., Singh, R. P., Loadman, P. M., Wilson, W., Hackshaw, A., Seumois, G., Okkenhaug, K., Thomas, G. J., Jones, T. M., Ay, F., Friberg, G., Kronenberg, M., Vanhaesebroeck, B., Vijayanand, P., Ottensmeier, C. H. (2022). Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. Nature, 605(7911), 741–746.
- Wu, H., Amirfakhri, S., Lin, H. H., Hollandsworth, H., Filemoni, F., Liu, Y., Wu, Y., Li, J., Xu, H., Chien, S., Bouvet, M., & Wang, Y. (2022). Monocytes engineered with iSNAP inhibit human B-lymphoma progression. Bioengineering & translational medicine, 7(2), e10285.
- Katrekar, D., Yen, J., Xiang, Y., Saha, A., Meluzzi, D., Savva, Y., & Mali, P. (2022). Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. Nature biotechnology, 40(6), 938–945.
-
Wu, T., Arevalo, C., Hsu, F. C., Hong, S., Parada, H., Jr, Yang, M., & Pierce, J. P. (2022). Independent and Joint Associations of Pessimism, Total Calorie Intake and Acid-Producing Diets with Insomnia Symptoms among Breast Cancer Survivors. Journal of clinical medicine, 11(10), 2828.
|
|
|
- RA2, Post Award (candidates hired into this position can work remotely, in-person or hybrid). Req #117071
- RA3 or RA2, Pre-Award (candidates hired into this position can work remotely, in-person or hybrid). – Req #117444
- Financial Analyst 1 – Req #116694
- Financial Analyst 2 – Req #117186
- Contracts and Grants Supervisor- Req #117223
- Research and Grant Writer – Req #116068
|
|
|
If you have newsworthy items to contribute, please contact our Marketing & Communications Manager, Renee Maude at amaude@health.ucsd.edu.
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and risk research, MCC researchers address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. MCC was founded in 1978, the same year it received its NCI designation.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
|
|
|
